Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-07
2011-11-22
Fay, Zohreh (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S912000
Reexamination Certificate
active
08063054
ABSTRACT:
A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and/or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter.
REFERENCES:
patent: 0 956 866 (1999-11-01), None
patent: WO 94/25033 (1994-11-01), None
patent: WO 99/42103 (1999-08-01), None
Henri Bernardi, et al. “ATP/ADP Binding Sites are Present in the Sulfonylurea Binding Protein Associated with Brain ATP-sensitive K+ channels” Biochemistry. Jul. 14, 1992;31(27):6328-32.
S. Celebi, et al. “Effects of Melatonin, Vitamin E and Octreotide on Lipid Peroxidation During Ischemia-Reperfusion in the Guinea Pig Retina” Eur J Ophthalmol. Mar.-Apr. 2002;12(2):77-83.
Hsiao-Ming Chao, et al. “Topically Applied Clonidine Protects the Rat Retina from Ischaemia/Reperfusion by Stimulating Alpha(2)-Adrenoceptors and not by an Action on Imidazoline Receptors” Brain Res. Jun. 15, 2001 15;904(1):126-36.
Pedro Cuevas, et al. “Systemic Administration of Acidic Fibroblast Growth Factor Ameliorates the Ischemic Injury of the Retina in Rats” Neurosci Lett. Oct. 9, 1998;255(1):1-4.
John E. Donello, et al. “Alpha(2)-Adrenoceptor Agonists Inhibit Vitreal Glutamate and Aspartate Accumulation and Preserve Retinal Function after Transient Ischemia” J Pharmacol Exp Ther. Jan. 2001;296(1):216-23.
Fabrice Duprat, et al. “The Neuroprotective Agent Riluzole Activates the Two P Domain K(+) channels TREK-1 and TRAAK” Mol Pharmacol. May 2000;57(5):906-12.
Mohamed Ettaiche, et al. “Riluzole Improves Functional Recovery after Ischemia in the Rat Retina” Invest Ophthalmol Vis Sci. Mar. 1999;40(3):729-36.
Mohamed Ettaiche, et al. “ATP-Sensitive Potassium Channels (K(ATP)) in Retina: A Key Role for Delayed Ischemic Tolerance” Brain Res. Jan. 26, 2001;890(1):118-29.
Valerie Fontaine, et al. “Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal lschemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2” J Neurosci. Apr. 1, 2002;22(7).
Catherine Heurteaux, et al. “K+ Channel Openers Prevent Global Ischemia-Induced Expression of c-fos, c-jun, Heat Shock Protein, and Amyloid Beta-Protein Precursor Genes and Neuronal Death in Rat Hippocampus” Proc Natl Acad Sci U S A. Oct. 15, 1993;90(20):9431-5.
Neville N. Osborne, et al. “Topical Flunarizine Reduces IOP and Protects the Retina Against Ischemia-Excitotoxicity” Invest Ophthalmol Vis Sci. May 2002;43(5):1456-64.
Gail M. Seigel, et al. “Inhibition of Neuroretinal Cell Death by Insulin-Like Growth Factor-1 and its Analogs” Mol Vis. Aug. 31, 2000;6:157-63.
Marta E. Szabo, et al. “Antioxidant Properties of Calcium Dobesilate in Ischemic/Reperfused Diabetic Rat Retina” Eur J Pharmacol. Oct. 5, 2001;428(2):277-86.
Wolf A. Lagreze, et al. “The Neuroprotective Properties of Gabapentin-Lactam” Graefes Arch Clin Exp Ophthalmol. Nov. 2001;239(11):845-9.
M. W. Hankins et al.,Consequences of Transient Retinal Hypoxia on Rod Input to Horizontal Cells in the Rat Retina, Vision Research, vol. 33, No. 4, Great Britain, Mar. 1993, pp. 429-436.
Frances M. Ashcroft et al.,New windows on the mechanism of action of KATP channel openers, Trends in Pharmacological Sciences, Elsevier Trends Journal, vol. 21, No. 11, Cambridge, Great Britain, Nov. 1, 2000, pp. 439-445.
Ettaiche Mohamed
Lazdunski Michel
Centre National de la Recherche Scientifique--CNRS
Fay Zohreh
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Universite de Nice-Sophia Antipolis
LandOfFree
Method of treatment of retinal ischemia with diazoxide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of retinal ischemia with diazoxide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of retinal ischemia with diazoxide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263409